The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study.
ANABOLICS
CLINICAL TRIALS
FRACTURE PREVENTION
FRACTURE RISK ASSESSMENT
OSTEOPOROSIS
Journal
JBMR plus
ISSN: 2473-4039
Titre abrégé: JBMR Plus
Pays: England
ID NLM: 101707013
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
10
12
2018
revised:
19
03
2019
accepted:
07
04
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
7
11
2019
Statut:
epublish
Résumé
Radiographic vertebral fractures (VFxs) are the most common fractures in osteoporosis and are associated with increased morbidity, mortality, and costs. A subset of VFxs manifest clinically, usually with a sudden onset of severe back pain. Romosozumab is a monoclonal antibody that binds and inhibits sclerostin, increasing bone formation and decreasing bone resorption, leading to rapid and large increases in bone density and strength and reduction in fracture risk. The FRAME (Fracture Study in Postmenopausal Women with Osteoporosis) study of postmenopausal women with osteoporosis demonstrated a significant reduction in new VFxs with romosozumab versus placebo. Here, we report the effect of romosozumab versus placebo on clinical VFx incidence over 12 months in women reporting back pain suggestive of VFxs. FRAME enrolled 7180 postmenopausal women with osteoporosis, mean age 70.9 years (hip
Identifiants
pubmed: 31687647
doi: 10.1002/jbm4.10211
pii: JBM410211
pmc: PMC6820457
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10211Informations de copyright
© 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Références
J Clin Densitom. 2016 Jan-Mar;19(1):8-22
pubmed: 26349789
Osteoporos Int. 2000;11(7):556-61
pubmed: 11069188
N Engl J Med. 2016 Oct 20;375(16):1532-1543
pubmed: 27641143
Injury. 2018 Aug;49(8):1393-1397
pubmed: 29983172
Clin Cases Miner Bone Metab. 2016 May-Aug;13(2):119-122
pubmed: 27920807
J Bone Miner Res. 1993 Sep;8(9):1137-48
pubmed: 8237484
Am J Med. 2016 Feb;129(2):221.e1-10
pubmed: 26524708
JAMA. 2001 Jan 17;285(3):320-3
pubmed: 11176842
J Bone Miner Res. 2012 Mar;27(3):645-53
pubmed: 22113888
Osteoporos Int. 2001;12(3):207-14
pubmed: 11315239
J Bone Miner Res. 2017 Jan;32(1):181-187
pubmed: 27487526
Osteoporos Int. 2019 Mar;30(3):601-609
pubmed: 30680431
Arch Intern Med. 1999 Jun 14;159(11):1215-20
pubmed: 10371229
J Bone Miner Res. 2017 Sep;32(9):1956-1962
pubmed: 28543940
Calcif Tissue Int. 2005 Apr;76(4):235-42
pubmed: 15812579
Bone Rep. 2016 Jul 30;5:186-191
pubmed: 28580386
Osteoporos Int. 2007 Dec;18(12):1617-24
pubmed: 17611706
Osteoporos Int. 2005 Dec;16(12):1823-6
pubmed: 16032373
Bone. 2017 Mar;96:63-75
pubmed: 27789417
J Bone Miner Res. 2013 Nov;28(11):2317-24
pubmed: 23616397
Am J Epidemiol. 2009 Nov 15;170(10):1290-9
pubmed: 19808632